Stockreport

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma Inc.  (LTRN) 
PDF HARMONICâ„¢ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion coho [Read more]